Vestmark Advisory Solutions’s BioNTech BNTX Stock Holding History

Vestmark Advisory Solutions’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,822	Closed	-$470K	–	862
2021 Q4	$470K	Sell	1,822 -128	-7%	-$35.1K	0.03%	559
2021 Q3	$532K	Sell	1,950 -1,211	-38%	-$385K	0.04%	474
2021 Q2	$708K	Buy	3,161 +1	+0%	+$189	0.05%	391
2021 Q1	$345K	Buy	+3,160	New	+$336K	0.03%	554

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Pendal Group Sydney, Australia $11.6B AUM 12.87% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Vestmark Advisory Solutions's BNTX Position: Q1 2022 in Review

Vestmark Advisory Solutions sold out of BioNTech (BNTX) in Q1 2022, closing a stake of 1,822 shares — an estimated $470K sold.

Vestmark Advisory Solutions first reported a position in BNTX in Q1 2021 and held it in 4 quarters. The position peaked at $708K in Q2 2021. 287 funds tracked by Wall St. Rank hold BNTX as of Q1 2022.

Vestmark Advisory Solutions reported no remaining BioNTech position as of Q1 2022 after selling out during the quarter.
Vestmark Advisory Solutions sold 1,822 BioNTech shares in Q1 2022, an estimated $470K.
Vestmark Advisory Solutions first reported a position in BioNTech in Q1 2021 and held it in 4 quarters.
Vestmark Advisory Solutions's BioNTech position peaked at $708K in Q2 2021.
287 funds tracked by Wall St. Rank held BioNTech as of Q1 2022.

Based on Vestmark Advisory Solutions's 13F filing for Q1 2022, filed 27 Apr 2022.